Drug Approval Rate Stagnant -- Nektar and ADVENTRX Look to Defy Odds
October 26 2011 - 8:16AM
Marketwired
Drug approvals from administrative bodies in both the U.S. and
Europe have been pivotal for biotech companies recently. Investors
have been particularly sensitive to decisions made on new drugs
considering the state of the global economic recovery. The Paragon
Report examines investing opportunities in the Biotechnology
Industry and provides equity research on Nektar Therapeutics
(NASDAQ: NKTR) and ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX).
Access to the full company reports can be found at:
www.paragonreport.com/NKTR www.paragonreport.com/ANX
While there are some success stories in the industry, a number
of players are having trouble dealing with the volatile nature of
biotechnologies. Research and development costs are extremely high,
and the success of a product can sometimes not be measured until
late in development. According to Krishan Maggon, a Geneva-based
pharmaceuticals consultant, the number of new biotech drugs
approved in the U.S. has remained in the 20 to 25 range during the
past four years, while in Europe the figure was a record-low 14
last year.
The Paragon Report provides investors with an excellent first
step in their due diligence by providing daily trading ideas, and
consolidating the public information available on them. For more
investment research on the biotechnology industry register with us
free at www.paragonreport.com and get exclusive access to our
numerous stock reports and industry newsletters.
Nektar Therapeutics (Nektar) is a clinical-stage
biopharmaceutical company developing a pipeline of drug candidates
that utilize its PEGylation and polymer conjugate technology
platforms. The Company's product pipeline consists of drug
candidates across a range of therapeutic areas, including oncology,
pain.
ADVENTRX Pharmaceuticals is a development-stage specialty
pharmaceutical company focused on in-licensing, developing and
commercializing product candidates for the treatment of cancer. The
company recently announced that it held a Type A meeting with the
U.S. Food and Drug Administration (FDA) to discuss the complete
response letter (CRL) it received in August from the FDA regarding
the Company's New Drug Application (NDA) for Exelbine (vinorelbine
injectable emulsion) for the treatment of non-small cell lung
cancer.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Adventrx (AMEX:ANX)
Historical Stock Chart
From Jul 2023 to Jul 2024